News | April 12, 2025
Morepen to add 1,000 medical representatives
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
The unique soap-fusion of Gondhoraj lime and neem provides a refreshing skin-friendly experience
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
The IND application supports the next phase of development of SBO-154
PRX-PLUS has a unique product feature with its deep-impacting formula
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
Subscribe To Our Newsletter & Stay Updated
